ADAM17 and colorectal carcinoma: To further investigate whether Notch signalling pathway mutations affect clinicopathological characteristics and the prognosis of patients with CRC, we analysed the clinicopathological characteristics and survival data between the mutation group (including NOTCH1, NOTCH2, NOTCH3, NOTCH4, FBXW7, NUMB, ADAM10, ADAM17 and γ‐secretase mutations) and the non‐mutation group.